[Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma]
Related Experiment Video
Updated: Oct 1, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
A Martínez García1, R Pérez García
1Licenciado en Medicina. Instituto Galego de Oftalmoloxia.
Purpose:
To determine the efficiency and safety of latanoprost in glaucoma patients previously treated with Betablockers.
Methods:
Latanoprost 0.005% was applied topically once daily without washing period in 60 eyes with primary open-angle glaucoma. The baseline intraocular pressure (IOP) was compared with post-latanoprost IOP for each yee. Responders were defined as those who had at least a 15% IOP reduction on latanoprost, whereas non-responders showed under 15% IOP reduction on latanoprost.
Results:
Baseline IOP of 23.50 S.D. 2.87 mm Hg (Mean SD) fell to 17.67 S.D. 1.62 mm Hg after 12 months of follow-up. Fifty-three eyes were responders, with an average IOP reduction of 28.28 S.D. 6.81%. Seven eyes were considered as non-responders with an average IOP reduction of 3.12% S.D. 2.98%. Five eyes (8.3%) had a demonstrable increase in iris pigmentation.
Conclusions:
Latanoprost, administered once daily, appears to be more active than betablockers in reducing intraocular pressure. Although further studies may be needed to confirm and evaluate the side effect of the increase in iris pigmentation (Arch Soc Esp Oftalmol 2002; 77: 269-274).
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Ophthalmic Drug Delivery Systems
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
